What is the diagnosis and treatment for a skin condition characterized by redness, itchiness, bullae (blisters) formation, rupture, ulceration, and healing with hyperpigmentation?

Bullous Pemphigoid

Diagnosis

Based on your clinical description—red, itchy skin progressing to bullae that rupture, ulcerate, and heal with hyperpigmentation—this presentation is most consistent with bullous pemphigoid (BP), the most common autoimmune blistering disease in elderly patients. 1

Clinical Features Supporting BP Diagnosis

• Age >70 years is a key diagnostic criterion, as BP typically affects the elderly 1, 2
• Tense bullae (not flaccid) arising on erythematous or normal-appearing skin, most commonly on flexural surfaces of limbs, inner thighs, and trunk 1
• Negative Nikolsky sign distinguishes BP from pemphigus vulgaris and Stevens-Johnson syndrome 2
• Pruritus may precede blister formation by weeks to months, and can be the sole initial manifestation 1, 3
• Absence of atrophic scarring after healing (though hyperpigmentation occurs) 1, 2
• Minimal or absent mucosal involvement (oral lesions occur in <20% of cases) 1, 2

Essential Diagnostic Tests

Direct immunofluorescence (DIF) from perilesional skin is the single most critical and essential test for diagnosis—it must show linear IgG and/or C3 deposits along the dermoepidermal junction 1, 3, 2

Additional confirmatory tests include:

• Histopathology from an early intact bulla showing subepidermal cleft with eosinophilic infiltrate 1, 2
• Serum ELISA for anti-BP180 and anti-BP230 antibodies (though DIF remains most critical) 1, 2
• Indirect immunofluorescence on salt-split skin showing IgG binding to the epidermal (roof) side of the split 1

Critical Medication History

Obtain detailed drug history for the past 1-6 months, specifically asking about:

• Diuretics (furosemide, spironolactone) 4
• Neuroleptics/psycholeptic drugs 3, 4
• Gliptins (DPP-4 inhibitors) 4
• Checkpoint inhibitors 3

Approximately 50% of drug-induced cases persist after drug withdrawal and require conventional treatment 4

---

Treatment

First-Line Treatment Based on Disease Extent

For localized/mild disease (<10% body surface area):

• Superpotent topical corticosteroids (clobetasol propionate) are the recommended first-line treatment 5, 6
• This approach avoids systemic corticosteroid toxicity in elderly patients 1

For moderate to severe/generalized disease:

Systemic corticosteroids remain the cornerstone of treatment, with prednisone indicated for bullous pemphigoid per FDA labeling 7

• Initial dose: Prednisolone 0.5 mg/kg/day orally 6
• This is lower than historical doses, reflecting modern understanding that high-dose steroids increase mortality risk in elderly BP patients 1

Adjuvant Immunosuppressive Therapy

Combine systemic corticosteroids with steroid-sparing agents to reduce cumulative corticosteroid exposure and associated morbidity 1, 5, 6:

• Doxycycline (anti-inflammatory properties) 6
• Dapsone (immunomodulant) 6
• Azathioprine or mycophenolate mofetil (for steroid-sparing effect) 5

Treatment Goals and Duration

The aim is to suppress clinical signs sufficiently to make disease tolerable (reduce blister formation, urticarial lesions, and pruritus), not necessarily achieve complete remission 1

• BP is self-limiting and usually remits within 5 years 1
• Mortality rates range from 6-41% in modern series, primarily due to complications of immunosuppression in elderly patients with multiple comorbidities 1
• High-dose immunosuppression may be more dangerous than the disease itself in this elderly population 1

Critical Pitfalls to Avoid

• Do not use high-dose systemic corticosteroids (>0.5 mg/kg/day) as initial therapy—this increases mortality without improving outcomes 1, 6
• Do not delay DIF testing—it can be performed after treatment initiation, though prolonged treatment reduces positive results 1
• Do not assume malignancy association—large series show no increased cancer incidence in BP patients compared to age-matched controls 1, 4
• Assess for neurological comorbidities (cerebrovascular disease, dementia, Parkinson's, epilepsy, multiple sclerosis), which are strongly associated with BP 4

Monitoring and Follow-up

• Evaluate general condition and comorbidities using Karnofsky performance status scale 1
• Monitor for corticosteroid adverse effects: hypertension, hyperglycemia, osteoporosis, infections, psychiatric symptoms 7
• Assess disease activity using validated tools (Bullous Pemphigoid Disease Activity Index) 1

---

Key Distinguishing Features from Other Blistering Diseases

Pemphigus vulgaris: Flaccid (not tense) bullae, positive Nikolsky sign, prominent mucosal involvement, intraepithelial (not subepidermal) split 2, 8, 9

Stevens-Johnson syndrome/TEN: Positive Nikolsky sign, extensive mucosal involvement, constitutional symptoms (fever, malaise), acute onset 2

Linear IgA disease: Only IgA (not IgG) on DIF 1